Related Articles
Efficacy and safety of oxaliplatin, bevacizumab and oral S‑1 for advanced recurrent colorectal cancer
Retrospective analysis of capecitabine and oxaliplatin (XELOX) plus bevacizumab as a first‑line treatment for Japanese patients with metastatic colorectal cancer
Phase I study of 5‑fluorouracil, leucovorin and bevacizumab in combination with radiation therapy in patients with locally advanced rectal cancer
Phase II trial of panitumumab with irinotecan as salvage therapy for patients with advanced or recurrent colorectal cancer (TOPIC study)
XELIRI regimen plus continuous treatment with bevacizumab is well-tolerated and effective in metastatic colorectal cancer patients in a second‑line setting involving the sequential administration of XELOX and XELIRI